GlobeNewswire Inc | Jun 9, 2021 08:00AM EDT

June 09, 2021

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.

Bruce Steel, Equilliums chief executive officer, will provide a high-level overview of itolizumabs mechanism of action and review each of the ongoing clinical programs, with a focus on topline data from the companys EQUATE study in acute graft-versus-host disease, to be presented at EHA on Friday, June 11, 2021. Mr. Steel and other members of Equilliums leadership team will be available for one-on-one meetings during the conference.

Date: Wednesday, June 16, 2021Time: 11:00 AM Eastern Time | 8:00 AM Pacific TimeLocation: Virtual Webcast

A live webcast of the presentation will be available under the Investors section of the Companys website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visitwww.equilliumbio.com.

Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications619-302-4431ir@equilliumbio.com

Media ContactsAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com